Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...

BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...

Eating too much sugar can contribute to heart disease, obesity, high cholesterol and high blood pressure. There is also an ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.

Gene that regulates energy balance shared by lab retrievers and humans, but researchers say effects can be over-ridden with a strict diet and exercise regime ...

Coronary artery disease (CAD), or the narrowing of the coronary arteries, is the leading cause of morbidity and mortality throughout the world. Atherosclerosis, or the buildup of plaque in the ...

This indicates that GLP-1 receptor agonists lead to greater reduction in overall body fat than that in muscle mass, resulting in an overall body fat percentage decrease of around 4.5%.